Compare Levi Strauss & Co. (LEVI) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs 10X Genomics Inc — how do they compare? Levi Strauss & Co. trades at $18.7 (market cap $7.31B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: 10X Genomics Inc is the larger of the two by market cap, and Levi Strauss & Co. pays a 3.36% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Levi Strauss & Co. for 70 Days and 10X Genomics Inc for 91 Days on average.
| LEVI | TXG | |
|---|---|---|
Market Cap | $7.31B | $10.07B |
Volume | 13,683,095 | 5,657,286 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $97.74 |
52-Week Low | $17.92 | $11.48 |
Typical Hold Time | 70 Days | 91 Days |
Enterprise Value | $8.86B | $9.59B |
Dividend Yield | 3.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss (LEVI) trades at $19.05, down 2.36% on the day, with a bearish technical signal but strong fundamentals. The company has beaten earnings estimates for four consecutive quarters, with Q3 2026 EPS of $0.48 exceeding expectations. Valuation metrics appear attractive with a P/E of 12.53 and P/S of 1.12, while profitability remains solid with a net income margin of 8.83% and ROE of 25.76%.
Wall Street maintains a bullish stance with 15 buy ratings and a consensus price target of $29.00, implying significant upside. However, technical indicators show bearish momentum, and risks include competitive pressures and recent cybersecurity incidents. The stock's current price near recent support levels presents a potential entry point for value-oriented investors.
10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.
The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
